Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 5,058 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Placebo, Laquinimod; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Dovitinib, Sorafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 34
States / cities: Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more

Conditions: Trichotillomania
Interventions: Placebo, N-Acetyl Cysteine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Campylobacter Infection
Interventions: Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Clostridium Difficile Infection
Interventions: Fecal Microbiota Therapy (FMT), Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Temporary Auditory Threshold Shift
Interventions: SPI-1005 Low dose, SPI-1005 Middle dose, SPI-1005 High dose, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years to 31 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Type 2, Diabetes Mellitus
Interventions: WB-011, Placebo, Continuous Glucose Monitor; Other · Device
Lead sponsor: Pendulum Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions: Colchicine, Diltiazem ER; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Iron-deficiency, Pregnancy Anemia, Obesity
Interventions: Jarrow Formulas Oral Bovine Lactoferrin Supplement; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes
Interventions: Semaglutide (Rybelsus®), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC585; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Opioid Use Disorder
Interventions: Psilocybin with facilitated counseling; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Obesity and Cardiovascular Risk
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 16
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Seladelpar, Placebos; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Acute Coronary Syndrome
Interventions: Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urinary Tract Infections
Interventions: Nitrofurantoin, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: ibrutinib, Correlative laboratory samples, quality of life assessment; Drug · Other
Lead sponsor: Kami Maddocks, MD; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Melanoma
Interventions: X4P-001, Pembrolizumab; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Atlanta, Georgia • Iowa City, Iowa • Houston, Texas + 1 more

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions: INCB028060; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland • Nashville, Tennessee

Conditions: PreDiabetes
Interventions: Low-dose bitter melon, High-dose bitter melon, Placebo; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Miami Gardens, Florida • Port Saint Lucie, Florida • Addison, Illinois

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Chronic Kidney Disease
Interventions: KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Search by objective public record fields.

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

N-Acetyl Cysteine in Trichotillomania

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

Nitrofurantoin and Urinary Tract Infections (UTIs)

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

A Dose-escalation Study in Subjects With Advanced Malignancies

Effects of Bitter Melon on Cardiometabolic Health

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease